Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis

INTRODUCTION: Lumacaftor/ivacaftor (LUM/IVA) has been shown to improve clinical outcomes in cystic fibrosis (CF) patients homozygous for Phe508del with forced expiratory volume in 1 s (FEV(1)) % pred >40%. We assessed the clinical utility of LUM/IVA in all eligible adult CF patients with FEV(1) %...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ERJ Open Res
Main Authors: King, Susannah J., Keating, Dominic, Williams, Elyssa, Paul, Eldho, Borg, Brigitte M., Finlayson, Felicity, Button, Brenda M., Wilson, John W., Kotsimbos, Tom
Formato: Artigo
Idioma:Inglês
Publicado em: European Respiratory Society 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7861032/
https://ncbi.nlm.nih.gov/pubmed/33569502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00203-2020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados